Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT) (HPCRT)

This study has been completed.
Sponsor:
Collaborators:
Baylor College of Medicine
Johns Hopkins University
Louisiana State University Health Sciences Center in New Orleans
Icahn School of Medicine at Mount Sinai
New Jersey Medical School
New York University School of Medicine
Northwestern University
University of California, Los Angeles
University of California, San Diego
University of California, San Francisco
University of Miami
University of North Carolina, Chapel Hill
University of South Florida
Information provided by (Responsible Party):
Johns Hopkins Bloomberg School of Public Health
ClinicalTrials.gov Identifier:
NCT00000142
First received: September 23, 1999
Last updated: October 14, 2015
Last verified: July 2015

September 23, 1999
October 14, 2015
April 1994
February 1996   (final data collection date for primary outcome measure)
Survival [ Time Frame: All patients enrolled will be followed until a common study closing date ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00000142 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)
Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)
To test and evaluate the efficacy and safety of intravenous cidofovir (Vistide, previously known as HPMPC) for the treatment of retinitis.

CMV (cytomegalovirus) retinitis is the most common intraocular infection in patients with AIDS and is estimated to affect 35 percent to 40 percent of patients with AIDS. Untreated CMV (cytomegalovirus) retinitis is a progressive disorder, the end result of which is total retinal destruction and blindness. As of September 1997, drugs approved by the United States Food and Drug Administration (FDA) for the treatment of CMV (cytomegalovirus)retinitis were ganciclovir (Cytovene), foscarnet (Foscavir), and cidofovir (Vistide). Cidofovir has a prolonged duration of effect permitting intermittent administration. All systemically administered anti-CMV drugs are given in a similar fashion consisting of initial 2-week high-dose treatment (induction) to control the infection followed by long-term lower dose treatment (maintenance) to prevent relapse. Cidofovir is administered as an intravenous infusion once weekly for induction therapy and once every 2 weeks as maintenance therapy. The HPCRT evaluated the efficacy and safety of cidofovir therapy.

The HPCRT was a multicenter, randomized, controlled clinical trial of cidofovir for the treatment of CMV (cytomegalovirus) retinitis. Patients with small peripheral CMV (cytomegalovirus) retinitis lesions (i.e., not at risk of immediate loss of visual acuity) were randomized to immediate treatment with cidofovir or deferred therapy until the retinitis had progressed. Patients randomized to immediate therapy received either 1) low-dose cidofovir at 5 mg/kg once weekly induction for 2 weeks, followed by 3 mg/kg once every 2 weeks for maintenance or 2) high-dose cidofovir at 5 mg/kg once weekly induction for 2 weeks followed by 5 mg/kg once every 2 weeks for maintenance. Patients whose retinitis progressed were given treatment according to best medical judgement, and those assigned to deferral were generally treated with cidofovir.

Outcomes in this trial included retinitis progression, loss of retinal area, and morbidity.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • HIV Infections
  • CMV Cytomegalovirus Retinitis
Drug: Cidofovir

Three groups:

  1. the deferral group, treatment deferred until retinitis progressed
  2. Low-dose cidofovir group, 5 mg/kg of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks.
  3. High-dose cidofovir group, 5mg/kg once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks.
Other Name: Vistide
  • Experimental: treatment deferral

    IV (in the vein) treatment deferred until retinitis progressed, either:

    5 mg/kg IV (in the vein) of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks, or

    5mg/kg IV (in the vein) once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks.

    Intervention: Drug: Cidofovir
  • Experimental: Cidofovir (low dose)
    5 mg/kg IV (in the vein) of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks
    Intervention: Drug: Cidofovir
  • Experimental: Cidofovir (high dose)
    5mg/kg IV (in the vein) once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks.
    Intervention: Drug: Cidofovir

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
64
February 1996
February 1996   (final data collection date for primary outcome measure)

Inclusion criteria:

  • diagnosis of AIDS according to the Centers for Disease Control and Prevention (CDC)
  • 13 years or older
  • Diagnosis of CMV (cytomegalovirus) retinitis as determined by a SOCA-certified Ophthalmologist.
  • At least one lesion whose size is one-quarter disc area or more that can be photographed.
  • Visual acuity in an affected eye of 3 or more lines on the (ETDRS) Early Treatment Diabetic Retinopathy Study chart at 1 meter distance (Snellen equivalent 8/200).
  • score of 60 or more on the Karnofsky scale.
  • Serum creatinine of 1.5mg/dL or less
  • less than 1+ proteinuria on urinalysis
  • Total bilirubin of 3.0 mg/dL or less
  • Hepatic transaminase levels that do not exceed 5 times the normal levels
  • Absolute neutrophil count of 750 cells/µL or greater
  • Platelet count of 50,000 cells/µL or greater
  • Hemoglobin of 7.5 g/dL or greater
  • Negative pregnancy test (females of childbearing potential)
  • All men/women of childbearing potential should practice birth control to prevent pregnancy while on study and for 3 months afterwards
  • Willingness/ability, with the assistance of a caregiver if necessary to comply with treatment and follow-up procedures
  • Signed consent statement

Exclusion criteria:

  • Evidence of a CMV (cytomegalovirus) retinitis lesion within zone 1. A lesion less than 1,500 µ from the margin of the optic disc or less than 3,000 µ from the center of the fovea in either eye excludes a patient.
  • Evidence of a CMV retinitis lesions that involves 25% or more of the retinal area regardless of location.
  • Previous or ongoing therapy for CMV (cytomegalovirus) disease with ganciclovir, foscarnet, CMV hyperimmune immunoglobulin, or other investigational agents solely as prophylaxis are eligible for enrollment.
  • Retinal detachment(s) in the affected eye(s)
  • media opacity that precludes visualization of the fundus of both eyes.
  • patients with a diagnosis of extraocular CMV (cytomegalovirus) disease.
  • Patients with history of clinically significant renal disease or renal dialysis.
  • Patients with history of clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia.
  • pregnant or lactating
  • patients with active medical problems including drug or alcohol abuse which could hinder compliance with treatment or follow-up procedures.
  • patients receiving therapy within the previous 7 days with nephrotoxic drugs, including: Amphotericin B, Vidarabine, Aminoglycoside antibiotics, Intravenous pentamidine. Patients receiving any of these drugs must discontinue the drug(s) at least one week prior to the time of enrollment, and for the duration of the trial period.
  • history of clinically significant probenecid allergy.
Both
13 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00000142
NEI-41
Yes
Not Provided
Not Provided
Johns Hopkins Bloomberg School of Public Health
Johns Hopkins Bloomberg School of Public Health
  • Baylor College of Medicine
  • Johns Hopkins University
  • Louisiana State University Health Sciences Center in New Orleans
  • Icahn School of Medicine at Mount Sinai
  • New Jersey Medical School
  • New York University School of Medicine
  • Northwestern University
  • University of California, Los Angeles
  • University of California, San Diego
  • University of California, San Francisco
  • University of Miami
  • University of North Carolina, Chapel Hill
  • University of South Florida
Study Chair: Douglas Jabs, MD Icahn School of Medicine at Mount Sinai
Johns Hopkins Bloomberg School of Public Health
July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP